Monitoring of Adverse Drug Reaction-Related Parameters in Children and Adolescents Treated With Antipsychotic Drugs in Psychiatric Outpatient Clinics

Lenneke Minjon 1*, Ivona Brozina 1, Toine C. G. Egberts 1,2, Eibert R. Heerdink 1,2,3 and Els van den Ban 4

1 Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, Netherlands, 2 Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, Netherlands, 3 Research Group Innovation of Pharmaceutical Care, University of Applied Sciences, Utrecht, Netherlands, 4 Karakter Child and Adolescent Psychiatry, Zwolle, Netherlands

Aim: To assess the frequency of monitoring of adverse drug reaction (ADR) related parameters in children and adolescents treated with antipsychotic drugs in psychiatric outpatient clinics and the considerations when monitoring was not performed.

Methods: This retrospective follow-up study included 100 randomly selected outpatients aged ≤18 years who had a first prescription of an antipsychotic drug recorded in the electronic medical records of psychiatric outpatient clinics between 2014 and 2017. They were followed for up to 3 years. This study assessed the frequency of monitoring for physical parameters (weight, height, body mass index, waist circumference, pulse, blood pressure, and an electrocardiogram) and laboratory parameters (glucose, lipids, and prolactin) before the first prescription of an antipsychotic drug as well as during its use. Monitoring frequencies were stratified by the patient characteristics (sex, age, cardiovascular risk factors, and use of other psychotropic drugs), and by location of antipsychotic drug initiation (psychiatric outpatient clinic or elsewhere). Additionally, this study assessed the considerations mentioned in the medical records for not monitoring ADR-related parameters.

Results: Overall, physical parameters were monitored more frequently (weight: 85.9% during the first half-year) than laboratory parameters (glucose and cholesterol: both 23.5%). There were no significant differences in monitoring at least one physical as well as in monitoring at least one laboratory parameter during the baseline period and during the total follow-up of antipsychotic drug treatment between the patient characteristics. In total, 3% of the children and adolescents were never monitored for any physical parameter, and 54% were never monitored for any laboratory parameter. For a minority of the children (14.8%) who were never monitored for laboratory parameters, considerations were recorded in their medical records, including refusal by the child or parents and monitoring performed by the general practitioner or elsewhere.
Conclusion: Monitoring frequencies of ADR-related parameters in children and adolescents treated with antipsychotic drugs in psychiatric outpatient clinics varied and especially monitoring of laboratory parameters was infrequent. Considerations why monitoring was not performed were rarely recorded. The optimal method of monitoring and documentation thereof should become clear to optimize the benefit-risk balance of antipsychotic drug treatment for each child.

Keywords: drug monitoring, adverse (side) effects, antipsychotic agents, child, adolescent, psychiatry, medical record

INTRODUCTION

Antipsychotic drugs are frequently prescribed to children and adolescents (hereafter referred to as children) to treat psychiatric disorders, including anxiety disorders, behavioral disorders, irritability associated with autism, tic disorders, and attention-deficit/hyperactivity disorder (ADHD) (1, 2). Prescribing is commonly off-label because the evidence for efficacy of these drugs in this young and vulnerable population is scarce (3, 4). Furthermore, it is well-documented that antipsychotic drugs frequently cause bothersome and even severe adverse drug reactions (ADRs), including cardiometabolic, endocrine, and extrapyramidal adverse effects (4, 5). Examples of these adverse effects include weight gain, hypertension, gynecomastia, and parkinsonism (4–6). These ADRs can differ in frequency and relative impact in children compared to adults (7). Children seem to be more likely to experience somnolence during antipsychotic drug treatment than adults; moreover, the extent of weight gain was found to be greater in children (8). Additionally, antipsychotic-induced hyperprolactinemia is more important in children because it may have an effect on pubertal development. ADRs can have both physical and emotional consequences and thereby negatively impact children's daily lives. Therefore next to monitoring efficacy, monitoring of ADRs is important to carefully evaluate and optimize the benefit-risk balance of antipsychotic drug treatment for each child.

The development of ADRs caused by antipsychotic drugs can be monitored through related parameters, including physical parameters (e.g., weight, height, body mass index (BMI), waist circumference, pulse, blood pressure, and heart examination) and laboratory parameters (e.g., glucose, lipids, and prolactin). Monitoring instructions of these parameters are available in clinical guidelines, and in regulatory drug product information such as the information leaflet (9–12). Despite the existing guidelines and instructions, previous studies have shown a large variability in the monitoring frequencies of ADR-related parameters, and that the overall monitoring frequencies were suboptimal (13–16). The majority of these studies used administrative databases from various settings, such as insurance companies or databases of general practitioners, but questionnaires about monitoring among prescribers have also been assessed (14, 16). In-depth assessments of the medical records of children treated with antipsychotic drugs is of added value in creating a complete overview of the total antipsychotic drug therapy of the individual child and what is actually monitored and recorded in daily clinical practice, including the considerations and choices made concerning (not) monitoring for ADR-related parameters.

The primary aim of this study was to assess the frequency of monitoring of ADR-related parameters in children treated with antipsychotic drugs in psychiatric outpatient clinics and the considerations when monitoring was not performed. The secondary aim was to compare differences in monitoring frequencies between sex, age categories, children with and without cardiovascular risk factors, children who were and were not prescribed other psychotropic drugs, and children who started the antipsychotic drug treatment within the psychiatric outpatient clinics and those who started this therapy elsewhere.

METHODS

Setting, Study Population, and Follow-Up

This retrospective follow-up study included 100 randomly selected outpatients aged ≤18 years treated with an antipsychotic drug within Karakter, a large Dutch academic child and adolescent psychiatry organization that operates in 12 locations and offers clinical and outpatient therapy to children aged ≤18 years from across the Netherlands. Children are referred to this organization by, for example, general practitioners, for diagnosis and treatment of various psychiatric disorders, including autism spectrum disorder, ADHD, conduct disorders, depression, anxiety, compulsive disorders, eating disorders, and psychosis.

Patients were eligible for inclusion if they had a first prescription of an antipsychotic drug (ATC code N05A, excluding lithium [N05AN01]) within one of the psychiatric outpatient clinics of Karakter recorded in the electronic medical records between January 2014 and December 2017 and were prescribed an antipsychotic drug more than once. The date of this first prescription (index date) was defined as having no prescription of an antipsychotic drug recorded within the electronic medical records of these psychiatric (outpatient) clinics during the 6 months prior. Children could either have started the antipsychotic drug treatment within one of the psychiatric outpatient clinics of Karakter or elsewhere, for example in another psychiatric clinic. All included children were followed from the index date until the end of antipsychotic drug use recorded within the medical record, transfer out of practice, December 2018, or 3 years of follow-up, whichever came first. During follow-up, children could switch to another type of
antipsychotic drug, and the period that a child was treated with an antipsychotic drug was considered to be continuous if the gap between the end date of one prescription and the start date of the next prescription was < 3 months. The children included were never hospitalized within one of the psychiatric clinics of Karakter during follow-up.

Approval for this study was obtained from the organization’s institutional review board (Karakter’s committee for human research; reference number 148-18). A review by a medical ethics committee was not required because of the observational nature of the study with no involvement in the children’s therapy or infringement of the psychological or physical integrity of the children. All data were recoded to secure privacy.

Data Collection

The electronic medical records were stored within a clinical information system linked to an electronic drug prescription system, which were used by the healthcare professionals to access and update medical records. Within the clinical information system information regarding the child’s psychiatric therapy could be consulted, including drug treatment, physical measurements, and the laboratory test results for blood glucose, lipids, and prolactin. The electronic drug prescription system also included information on the physical measurements weight, height, BMI, pulse, and blood pressure. Both systems were used to collect the data needed for this study.

Standard operational procedures (SOPs) and a checklist were used during data collection to ensure validity. Each SOP described the location of specific information in the electronic medical records, including patient characteristics, psychiatric and somatic diagnoses, diagnoses in family history, previous and current drug use, the (main) physician of the child, test requests, physical and laboratory test results, referrals, and the location of antipsychotic drug initiation. While collecting the data, patient numbers were recoded to ensure privacy.

Medical record review and data entry were conducted by two reviewers, and seven medical records were also reviewed by the first author to check for discrepancies. Discrepancies and ambiguities of all medical records were discussed and resolved by consensus with the first author as well as the additional co-authors.

Outcomes

Baseline information up to 31 days before the index date (start of antipsychotic drug) was collected, as well as data in 6-month timeframes (182 days) during follow-up. We assessed whether children were monitored for each ADR-related physical and laboratory parameter at least once during the baseline period, to assess if monitoring outcomes at the start of the antipsychotic drug treatment were known, and at least once during each fixed 6-month timeframe thereafter. When the follow-up time of antipsychotic drug use did not cover the complete final 6-month timeframe, this timeframe was excluded, and follow-up was censored at the end of the previous timeframe. The physical parameters included weight, height, BMI, waist circumference, pulse, blood pressure, and an electrocardiogram (ECG) and the laboratory parameters included glucose, cholesterol, low-density lipoproteins (LDL), high-density lipoproteins (HDL), triglycerides, and prolactin, based on the available clinical guidelines regarding monitoring (9, 10). A child was considered to be monitored in a certain timeframe in case the result of the monitoring parameter was recorded in the medical record of that child.

Determinants

Differences in monitoring frequencies of the ADR-related physical and laboratory parameters across the following patient characteristics were determined: (1) sex, (2) age categories (0–11 and 12–18 years old at the index date), (3) children with a cardiovascular risk factor at the index date and children without these risk factors, and (4) children who were prescribed other psychotropic drugs within the 6 months before, up to and including the index date, and children who were not prescribed other psychotropic drugs during this period. Additionally, differences in monitoring frequencies of the ADR-related physical and laboratory parameters were determined between children who started the antipsychotic drug treatment within the psychiatric outpatient clinics and those who started this therapy elsewhere. Cardiovascular risk factors were defined as having a recorded diagnosis of diabetes mellitus, hyperlipidemia, cardiovascular disorder, or overweight, hyperlipidemia according to the laboratory results or overweight according to the BMI measurement results. For the laboratory results, the reference values were included in the same document. The BMI measurement results were compared to the cutoff values described in a guideline for pediatricians (17).

Considerations

Furthermore, this study assessed the considerations when monitoring of ADR-related physical and laboratory parameters was not performed during the antipsychotic drug treatment, which was defined as having no monitoring results included within the medical records.

Data analysis

Descriptive statistics were used to determine the percentage of children monitored for each physical and laboratory parameter at least once during the baseline period and every fixed 6-month timeframe thereafter. Additionally, the percentage of children was determined who had been monitored for at least one of the physical and at least one of the laboratory parameters during the baseline period and during the total follow-up period thereafter. Monitoring frequencies were stratified by sex, age categories, cardiovascular risk factors at baseline, use of other psychotropic drugs within the 6 months before, up to and including the index date, and location of initiation of the antipsychotic drug treatment. Relative risks (RRs) and 95% confidence intervals (95% CIs) were calculated when comparing strata. Statistical analyses were performed using SPSS Statistics version 25.
RESULTS

There were 1,877 outpatients who received a prescription of an antipsychotic drug within one of the psychiatric outpatient clinics between 2014 and 2017, who were prescribed an antipsychotic drug more than once, and who were never hospitalized within one of these psychiatric clinics during follow-up. One hundred children were randomly selected (Table 1), including only those who were \( \leq 18 \) years of age at the index date and who did not have an antipsychotic drug prescription within these psychiatric (outpatient) clinics during the 6 months prior to the index date. The majority of the included children were male (79.0%), aged 6–11 years (52.0%), were prescribed risperidone at baseline (59.0%), had the initial antipsychotic drug prescription within one of the psychiatric outpatient clinics (85.0%), and were diagnosed with an autism spectrum disorder (80.0%).

Monitoring of Physical and Laboratory Parameters

Overall, physical parameters were monitored more frequently than laboratory parameters (Figures 1A, B). The physical parameter weight was monitored most frequently in children during the baseline period (74.0%) compared to the other physical and laboratory parameters. After 6 months, 85 children were still treated with an antipsychotic drug, and the physical parameters monitored most frequently in these children during this first half-year of antipsychotic drug treatment were weight (\( n = 73; 85.9% \)) and height (\( n = 66; 77.6% \)), and the laboratory parameters monitored most frequently were glucose and cholesterol (both \( n = 20; 23.5% \)). None of the children were monitored for waist circumference or ECG during the first half-year of treatment.

In total, 75.0% of the children were monitored at least once for one of the physical parameters during the baseline period and 92.0% during the total follow-up of antipsychotic drug treatment thereafter (Figure 1A). Additionally, 11.0% of the children were monitored at least once for one of the laboratory parameters during the baseline period and 40.0% during the total follow-up of antipsychotic drug treatment thereafter (Figure 1B). Of those children who were not monitored during the baseline period for any physical parameter (\( n = 25 \)), three (12.0%) were monitored for at least one physical parameter within the first week of antipsychotic drug treatment. Of those children who were not monitored during the baseline period for any laboratory parameter (\( n = 89 \)), nine (10.1%) were monitored for at least one laboratory parameter within the first week of antipsychotic drug treatment.

Determinants

There were no significant differences in monitoring of at least one physical parameter as well as in monitoring of at least one laboratory parameter during the baseline period and during the antipsychotic drug treatment thereafter between the patient characteristics, including sex, age categories, cardiovascular risk factors at the start of antipsychotic drug treatment, and use of other psychotropic drugs within the 6 months before the start of antipsychotic drug treatment (Table 2).

---

**TABLE 1** | Characteristics of the study population (\( n = 100 \)).

| Characteristic                          | \( n \) | (%)  |
|----------------------------------------|--------|------|
| **Sex**                                |        |      |
| Females                                | 21     | (21.0)|
| Males                                  | 79     | (79.0)|
| **Age at index date (years)**          |        |      |
| 0–5                                    | 9      | (9.0)|
| 6–11                                   | 52     | (52.0)|
| 12–18                                  | 39     | (39.0)|
| **Year of index date**                 |        |      |
| 2014                                   | 27     | (27.0)|
| 2015                                   | 29     | (29.0)|
| 2016                                   | 24     | (24.0)|
| 2017                                   | 20     | (20.0)|
| **Total duration of follow-up (years)**|        |      |
| < 0.5                                  | 15     | (15.0)|
| 0.5–1.0                                | 19     | (19.0)|
| 1.0–1.5                                | 19     | (19.0)|
| 1.5–2.0                                | 11     | (11.0)|
| 2.0–2.5                                | 7      | (7.0)|
| 2.5–3.0                                | 9      | (9.0)|
| 3.0                                    | 20     | (20.0)|
| **Antipsychotic drug prescribed (at index date)** |    |      |
| Risperidone                            | 59     | (59.0)|
| Aripiprazole                           | 22     | (22.0)|
| Pipamperone                            | 10     | (10.0)|
| Olanzapine                             | 4      | (4.0)|
| Quetiapine                             | 4      | (4.0)|
| Haloperidol                            | 1      | (1.0)|
| **Initial antipsychotic drug prescription** |    |      |
| Within the psychiatric clinic          | 85     | (85.0)|
| Elsewhere                              | 15     | (15.0)|
| **Psychiatric disorders (ever before index date)** |    |      |
| Autism spectrum disorder               | 80     | (80.0)|
| Attention-deficit / hyperactivity disorder | 47     | (47.0)|
| Intellectual disability                 | 17     | (17.0)|
| Anxiety disorder (incl. OCD, PTSD, phobia) | 16     | (16.0)|
| Mood disorder                          | 11     | (11.0)|
| Tic disorder                           | 11     | (11.0)|
| Behavioral disorder                    | 9      | (9.0)|
| Eating disorder                        | 4      | (4.0)|
| Sleeping disorder                      | 4      | (4.0)|
| Other                                  | 23     | (23.0)|
| >1 psychiatric disorder (included above) | 76     | (76.0)|
| **Somatic disorders/problems (ever before index date)** |    |      |
| Genetic/ congenital/metabolic           | 15     | (15.0)|
| Allergies/asthma/eczema                 | 11     | (11.0)|
| Overweight/obesity                     | 11     | (11.0)|
| Gastrointestinal/incontinence           | 7      | (7.0)|
| Epileptic disorder                     | 5      | (5.0)|
| Urinary                                | 5      | (5.0)|
| Fetal alcohol syndrome/neonatal abstinence syndrome | 4 | (4.0)|

(Continued)
Table 1 Continued

| Characteristic                       | n  | (%) |
|--------------------------------------|----|-----|
| Underweight                         | 3  | (3.0) |
| Hyperlipidemia                       | 2  | (2.0) |
| Cardiovascular                       | 1  | (1.0) |
| Other                                | 9  | (9.0) |

Psychotropic drug use (6 months before index date)*

| Drug Type                        | n  | (%) |
|----------------------------------|----|-----|
| Stimulants and atomoxetine       | 33 | (33.0) |
| Hypnotics/sedatives              | 26 | (26.0) |
| Antidepressants                   | 6  | (6.0) |
| Antidesegens and lithium          | 7  | (7.0) |

Somatic drug use (6 months before index date)*

| Drug Type                        | n  | (%) |
|----------------------------------|----|-----|
| Antihistamines                    | 7  | (7.0) |
| Oral inhalers and montelukast    | 6  | (6.0) |
| Antiepileptic drugs              | 3  | (3.0) |
| Other                            | 21 | (21.0) |

Index date: first prescription of an antipsychotic drug recorded in the electronic medical records of the psychiatric outpatient clinic.

OCD, obsessive–compulsive disorder; PTSD, post–traumatic stress disorder.

*Total duration of follow-up (years): mean 1.6, median 1.4.

| Drug Type                        | n  | (%) |
|----------------------------------|----|-----|
| ADHD, Attention deficit disorder | 1  | (1.0) |
| Antidepressants                   | 6  | (6.0) |
| Antipsychotics                    | 5  | (5.0) |
| Antiepileptic drugs              | 3  | (3.0) |
| Other                            | 21 | (21.0) |

Also no significant differences between children who started the antipsychotic drug treatment within one of the psychiatric outpatient clinics and those who started this therapy elsewhere.

Assessing each physical and laboratory parameter separately, there were only few significant differences found regarding the monitoring frequency during the baseline period and during the first 6 months of antipsychotic drug treatment within one of the psychiatric outpatient clinics. There were no significant differences in monitoring between males and females (Figure 2A), but there were significant differences between the two age categories, as the physical parameters height and blood pressure were monitored relatively less frequently in children aged 12–18 years than in children aged 0–11 years (RR [95% CI]: 0.7 [0.6–1.0] and 0.7 [0.4–1.0], respectively) during the first 6 months of antipsychotic drug treatment (Figure 2B). Overall, children who were treated with other psychotropic drugs within the 6 months before the start of the antipsychotic drug treatment were monitored relatively more frequently during the baseline period and during the first 6 months thereafter for the majority of physical parameters compared to children not treated with other psychotropic drugs, but the only significant difference was found in monitoring for pulse during the baseline period (RR [95% CI]: 1.6 [1.1–2.5]). There were also no significant differences in monitoring for weight and waist circumference, as weight was monitored relatively more often in children who started the antipsychotic drug treatment within one of the psychiatric outpatient clinics compared to elsewhere (RR [95% CI]: 1.5 [1.0–2.3]) during the first 6 months of antipsychotic drug treatment within one of the psychiatric outpatient clinics, and waist circumference was monitored relatively less often in children who started the antipsychotic drug treatment within one of the psychiatric outpatient clinics compared to elsewhere (RR [95% CI]: 0.2 [0.0–0.8]) during the baseline period.

Considerations

Of all included children, three were never monitored for any physical parameter during the baseline period or during the follow-up of antipsychotic drug treatment thereafter, and 54 were never monitored for any laboratory parameter. Regarding the three children who were never monitored for physical parameters, considerations why monitoring was not performed were not mentioned in their medical records. For eight of the 54 children (14.8%) who were never monitored for laboratory parameters, considerations for this lack of monitoring results were recorded in their medical records. The considerations or reasons included refusal by the child (e.g., fear of needles; n = 4) or parents (n = 1) and monitoring performed by the general practitioner or elsewhere (n = 4), but these results were not recorded in the medical records of the psychiatric outpatient clinic.

In the medical records of children who were monitored at least once for physical parameters during the baseline period or during the follow-up of antipsychotic drug treatment (n = 97), refusal by the child was mentioned in two medical records (2.1%). It was mentioned within several medical records that monitoring of physical parameters was also performed by the parents (n = 12; 12.4%), general practitioner (n = 10; 10.3%), or pediatrician (n = 2; 2.1%), though it was not clear if these monitoring results were always recorded in the medical records of the psychiatric outpatient clinics. In the medical records of children who were monitored at least once for laboratory parameters during the baseline period or during follow-up (n = 46), considerations for a delay in monitoring or a lack of results included also refusal by the child (n = 5; 10.9%), delay caused by the parents (n = 2; 4.3%), monitoring of glucose by the parents (n = 1; 2.2%), or monitoring performed elsewhere (n = 5; 10.9%), but the results were not recorded in the medical records of the psychiatric outpatient clinic.

Discussion

Although most physical parameters were monitored more frequently than laboratory parameters in children treated with antipsychotic drugs in psychiatric outpatient clinics, the monitoring frequencies for the majority of the parameters were low. There were no significant differences in monitoring of ADR-related parameters between sex and between children with and without cardiovascular risk factors at the start of the antipsychotic drug treatment, and only a few between age...
categories (height and blood pressure), children who did or did not use other psychotropic drugs within the 6 months before the start of the antipsychotic drug treatment (pulse), and between the initiation of the antipsychotic drug treatment at the psychiatric outpatient clinics or elsewhere (weight and waist circumference). The considerations when there were no monitoring results included in the medical records were only occasionally reported, as, for example, this was only mentioned for 14.8% of the children who were never monitored for laboratory parameters. Considerations mentioned included refusal by the child or parents and monitoring performed by the general practitioner or elsewhere.

Although previous studies have shown differences in monitoring frequencies in children treated with antipsychotic drugs, it is clear that the monitoring frequencies were suboptimal (13, 15, 16, 18). Overall, it has been shown that the physical parameter weight was monitored more frequently in children treated with antipsychotic drugs compared to the laboratory parameters glucose and lipids, and waist circumference was monitored much less, which is in line with the results of this current study (14, 15, 19).

Some differences in monitoring frequencies across sex and age categories were indicated in this study. Although this current study showed no significant differences between sex, it seemed that boys were monitored relatively more frequently than girls. This study demonstrated significant differences between age categories (0–11 and 12–18 years) in monitoring for the physical parameters height and blood pressure, but there were no significant differences in monitoring for laboratory parameters. However, higher monitoring frequencies of laboratory parameters in older children were demonstrated in previous studies (20, 21). This result could also have been expected in the current study, as these differences in monitoring frequencies of laboratory parameters could be due to the fear of needles, which is generally more common in younger children (22).

Especially the monitoring frequencies of the laboratory parameters were low. Monitoring instructions of parameters are available in clinical guidelines, but these guidelines differ in which parameters they recommend to monitor and the frequency of monitoring (9–11, 23). Although there is no national clinical guideline in the Netherlands for monitoring of ADR-related parameters in children treated with antipsychotic drugs, the guideline of Accare, a large academic mental health organization for child and adolescent psychiatry in the northern part of the Netherlands, is widely used by other Dutch healthcare professionals and is published on the national website for child and adolescent psychiatry (https://www.kenniscentrum-kjp.nl/) (9). Strict use of this guideline varies among prescribers, also within Karakter. The low monitoring frequencies of the laboratory parameters could be due to the recommendation of this guideline to monitor the parameters glucose and lipids only at baseline and every 6 months thereafter when there are risk factors present. One of these risk factors is overweight. However, no significant differences were shown by this study between children with and without cardiovascular risk factors, including overweight. Overweight was the most reported cardiovascular risk factor within this study. The risk factors hyperlipidemia and diagnosis for a cardiovascular disorder were only reported in few medical records, and diabetes mellitus in none. This
could be because these disorders are rare in children, or this information was not well-reported in the medical records and therefore missing.

Previous studies have shown suboptimal monitoring frequencies in children treated with antipsychotic drugs and low compliance to monitoring guidelines (15, 20, 24). Improvement in monitoring practices is needed, which is seen not only in children treated with antipsychotic drugs, but also the monitoring frequencies for adults treated in psychiatric outpatient clinics have been shown to be suboptimal according to the guidelines (25). Additionally, low monitoring frequencies are not only related to antipsychotic drug use, as low monitoring frequencies and poor adherence to clinical guidelines have also been demonstrated concerning other psychotropic drugs, including lithium, as well as somatic drugs (26–28).

As this study showed only minor differences in monitoring frequencies between patient characteristics, including sex, age categories, and children with and without risk factors present, and suboptimal monitoring frequencies were also shown by other studies including adults and other types of drugs, the reasons for suboptimal monitoring might be with the healthcare professionals (or the system) or children and caregivers themselves. Suboptimal monitoring by the healthcare professionals could be caused by the lack of a clear national clinical guideline, insufficient collaboration with other healthcare professionals, low confidence about monitoring, a lack of a reminder system or insufficient access to the equipment needed, for example a blood pressure machine (29). Despite the lack of a national guideline, the majority of the prescribers of antipsychotic drugs to children are aware that they should monitor for ADRs (14). However, when collaborating with other health care professionals, it is not always clear who is responsible to monitor for ADRs (29–31). As shown in this current study, children could also be monitored by the general practitioner or pediatrician, though it was not always clear which exact parameters were monitored elsewhere and if the results were recorded in the medical records of the psychiatric outpatient clinics, since the electronic systems were not linked. A gap between monitoring for ADRs and the rest of the antipsychotic drug treatment is concerning, as it could lead to poor monitoring, undetected abnormalities in ADR-related physical and laboratory parameters, and insufficient follow-up of the antipsychotic drug treatment. An electronic system for medical records could enhance the monitoring practices by more easily sharing monitoring results and defining whose responsibility it is to monitor the children (29). Electronic medical records do also facilitate as they improve the quality of outpatient clinic notes, including information about ADRs and follow-up information (32). However, documentation quality varies between healthcare professionals and type of care measure.

### TABLE 2 | Monitoring of adverse drug reaction-related parameters in children and adolescents treated with antipsychotic drugs in psychiatric outpatient clinics: stratified by sex, age, cardiovascular risk factors, use of other psychotropic drugs, and location of antipsychotic drug initiation.

|                 | Physical parameters | Laboratory parameters |
|-----------------|---------------------|-----------------------|
|                 | Baseline | Follow-up | Baseline | Follow-up |
|                  | n | % | RR [95% CI] | % | RR [95% CI] | n | % | RR [95% CI] | % | RR [95% CI] |
| **Sex**         |   |   |          |   |          |   |   |          |   |          |
| Female          | 21 | 66.7 | 1 (ref) | 85.7 | 1 (ref) | 9.5 | 1 (ref) | 23.8 | 1 (ref) |
| Male            | 79 | 77.2 | 1.2 [0.8–1.6] | 93.7 | 1.1 [0.9–1.3] | 11.4 | 1.2 [0.3–5.1] | 44.3 | 1.9 [0.8–4.2] |
| **Age**         |   |   |          |   |          |   |   |          |   |          |
| 0–11 years old  | 61 | 77.0 | 1 (ref) | 96.7 | 1 (ref) | 16.4 | 1 (ref) | 34.4 | 1 (ref) |
| 12–18 years old | 39 | 71.8 | 0.9 [0.7–1.2] | 84.6 | 0.9 [0.8–1.0] | 2.6 | 0.2 [0.0–1.2] | 48.7 | 1.4 [0.9–2.3] |
| **Cardiovascular risk factor** |   |   |          |   |          |   |   |          |   |          |
| No              | 86 | 74.4 | 1 (ref) | 91.9 | 1 (ref) | 10.5 | 1 (ref) | 40.7 | 1 (ref) |
| Yes             | 14 | 78.6 | 1.1 [0.8–1.4] | 92.9 | 1.0 [0.9–1.2] | 14.3 | 1.4 [0.3–5.7] | 35.7 | 0.9 [0.4–1.9] |
| **Other psychotropic drugs** |   |   |          |   |          |   |   |          |   |          |
| No              | 48 | 72.9 | 1 (ref) | 91.7 | 1 (ref) | 14.6 | 1 (ref) | 41.7 | 1 (ref) |
| Yes             | 52 | 76.9 | 1.1 [0.8–1.3] | 92.3 | 1.0 [0.9–1.1] | 7.7 | 0.5 [0.2–1.7] | 38.5 | 0.9 [0.6–1.5] |
| **Initiation at the psychiatric clinic** |   |   |          |   |          |   |   |          |   |          |
| No              | 15 | 60.0 | 1 (ref) | 86.7 | 1 (ref) | 6.7 | 1 (ref) | 33.3 | 1 (ref) |
| Yes             | 85 | 77.6 | 1.3 [0.8–2.0] | 92.9 | 1.1 [0.9–1.3] | 11.8 | 1.8 [0.2–12.8] | 41.2 | 1.2 [0.6–2.6] |

*Children and adolescents who were monitored for at least one physical and for at least one laboratory parameter during the baseline period and during the total follow-up of antipsychotic drug treatment thereafter.*

*Baseline period: a maximum of 1 month before the first prescription of an antipsychotic drug in the psychiatric outpatient clinic, up to and including the date of this first prescription.*

*Cardiovascular risk factors at baseline: diagnosis for overweight or overweight according to the body mass index measurements (n = 11), diagnosis for hyperlipidemia or hyperlipidemia according to the laboratory results (n = 2), diagnosis for a cardiovascular disorder (n = 1), diagnosis for diabetes mellitus (n = 0).*

*Use of other psychotropic drugs within the 6 months before the first prescription of an antipsychotic drug within the psychiatric outpatient clinic, up to and including the date of the first prescription.*

*n, number of children and adolescents.

RR [95%CI], relative risk [95% confidence interval].
in regard to medication, drug allergies, and compliance with guidelines (33), as also seen in this current study. Electronic systems should be equipped to suit the needs of healthcare professionals in the evaluation and monitoring of ADRs in children treated with antipsychotic drugs (34). For example, this electronic system should also include a reminder system, not only to remind the healthcare professional that monitoring should be performed, but also to assess the parameters outcomes, for example laboratory parameters, on a later moment in time. Furthermore, the children and the caregivers play an important and active role in optimizing monitoring practices. Barriers related to the children of caregivers are refusal by the child, for example because of a fear of needles, as also shown in this study, or the caregivers who resist or simply forget to obtain the laboratory tests (35). Clear instructions and information tailored to the patient would improve monitoring practices (36). Additionally, it is important that the healthcare professional is aware of the barriers present and can anticipate the specific situation.

A strength of this study was that by reviewing the electronic medical records, a complete overview was gained of the total antipsychotic drug therapy of the individual child in the psychiatric outpatient clinics. Medical records review and data entry were conducted by only two reviewers, who used SOPs and the checklist to gather the information needed, which ensured that they gathered information consistently and no important files in the medical records were missed. However, this study also has some limitations. This study included a relatively small number of children in one mental healthcare institution in the Netherlands, although there were multiple locations involved. Especially the numbers when separating in different patient characteristics and the location of initiation of the antipsychotic drug treatment were small. To compare these groups was the secondary aim of the study. More research is needed to detect differences between those groups. The diagnoses (Table 1) were those reported in the medical records and we did not validate these diagnoses. However, this does not influence the results of this study as a child treated with an antipsychotic drug should be monitored regardless of the diagnosis. Fifteen children were prescribed an antipsychotic drug elsewhere before they were transferred to one of the psychiatric outpatient clinics, which could lead to a difference in documentation history compared to the children who started the antipsychotic drug treatment within the psychiatric outpatient clinics. Some children did not
have 1 month of valid data available before the index date. Data collected depended on what was reported within the records, and notes could be missing, unclear, or incomplete. However, for this study also the free texts within a medical record were taken into account. Even if missing or unclear data has led to an underestimation of the monitoring frequencies, this would also deteriorate the quality and completeness of the medical records in the psychiatric outpatient clinics in daily clinical practice, and could lead to an incomplete transfer of information to other internal and external healthcare professionals.

Clinical Implications
By monitoring children treated with antipsychotic drugs, abnormalities in ADR-related physical and laboratory parameters can come to light, and interventions can be performed to optimize the benefit-risk balance of the antipsychotic drug treatment for each child, including lowering the dosage, switching to another drug, a referral to a dietitian or consulting a pediatrician. When monitoring is suboptimal, this could cause severe risks, as abnormalities in blood glucose and a high body weight could result in the development of diabetes mellitus, and abnormalities in blood prolactin levels could lead to gynecomastia and galactorrhea (37, 38). On the other hand, when the monitoring frequency is excessive, this not only increases the healthcare costs, causes unneeded time investments and an administrative burden for the healthcare professionals, this can also impact the child’s quality of life, considering the fear of needles and the constant reminder of the psychiatric disorder with which the child has been diagnosed. Further research is needed to gain knowledge about the optimal method of monitoring for ADR-related parameters in children, which should be captured in a clear national clinical guideline to prevent children from developing severe ADRs and to optimize the benefit-risk balance in the individual child.

CONCLUSION
Overall, monitoring frequencies of ADR-related parameters in children treated with antipsychotic drugs in psychiatric outpatient clinics varied and especially monitoring of the laboratory parameters was low. There were no prominent differences in monitoring between patient characteristics, for example across sex and age categories. Considerations why monitoring was not performed were rarely recorded within the medical records. By gaining more knowledge concerning the optimal frequency of monitoring and the facilitators and barriers for monitoring in psychiatric outpatient clinics as well as for each child, monitoring practices could be improved. Monitoring leads to knowledge about the effects of the antipsychotic drug treatment in the individual child, which is essential to evaluate and improve the benefit-risk balance of the therapy.

DATA AVAILABILITY STATEMENT
The datasets presented in this article are not readily available because the dataset includes information from psychiatric outpatient clinics (for children and adolescents). Requests to access the datasets should be directed to Lenneke Minjon, l.minjon@uu.nl.

ETHICS STATEMENT
The studies involving human participants were reviewed and approved by Karakter’s committee for human research (institutional review board; reference number 148-18). Written informed consent from the participants’ legal guardian/next of kin was not required to participate in this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS
Material preparation and data collection were performed by LM, IB, and EB. Analysis was performed by LM, IB, and EH. The first draft of the manuscript was written by LM. All authors commented on previous versions of the manuscript, contributed to the study conception and design, read and approved the final manuscript.

FUNDING
The authors declare that the study was solely funded by Utrecht University.

ACKNOWLEDGMENTS
The authors would like to thank the employees of Karakter whose participation made the study possible, especially Joset Arends-Kolker, Wilco Jansen, Jan Meerman, and Roelanda Reijntjes. The authors also wish to thank Juul Aarts for her help with collecting the data.

REFERENCES
1. Pringsheim T, Stewart DG, Chan P, Tehrani A, Patten SB. The pharmacoepidemiology of psychotropic medication use in Canadian children from 2012 to 2016. J Child Adolesc Psychopharmacol. (2019) 29:740–5. doi: 10.1089/cap.2019.0018
2. Kaguelidou F, Holstiege J, Schink T, Bezemer I, Poluzzi E, Mazzaglia G, et al. Use of antipsychotics in children and adolescents: a picture from the ARITMO population-based European cohort study. Epidemiol Psychiatr Sci. (2020) 29:e117. doi: 10.1017/S2045796020000293
3. Sohn M, Moga DC, Blumenschein K, Talbert J. National trends in off-label use of atypical antipsychotics in children and adolescents in the United States. Medicine (Baltimore). (2016) 95:e3784. doi: 10.1097/MD.0000000000003784
4. Krause M, Zhu Y, Huhn M, Schneider-Thoma J, Bigelli I, Chaimani A, et al. Efficacy, acceptability, and tolerability of second generation antipsychotics in children and adolescents with schizophrenia: a network meta-analysis. Eur Neuropsychopharmacol. (2018) 28:659–74. doi: 10.1016/j.euroneuro.2018.03.008
5. Pisano S, Catone G, Velti S, Lanzara V, Pozzi M, Clementi E, et al. Update on the safety of second generation antipsychotics in youths: a call for
collaboration among paediatricians and child psychiatrists. Ital J Pediatr. (2016) 42:51. doi: 10.1186/s13052-016-0259-2
6. Minjon L, van den Ban E, de Jong E, Souverie PC, Egberts TCG, Heerdink ER. Reported adverse drug reactions in children and adolescents treated with antipsychotics. J Child Adolesc Psychopharmacol. (2019) 29:124–32. doi: 10.1089/cap.2018.0013
7. Liu X, Schuette P, Burckart GJ, Green DJ, La J, Burnham JM, et al. A comparison of pediatric and adult safety studies for antipsychotic and antidepressant drugs submitted to the United States Food and Drug Administration. J Pediatr. (2019) 208:236–42. doi: 10.1016/j.jpeds.2018.12.033
8. Correll CU, Sheridan EM, DelBello MP. Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Discord. (2010) 12:116–41. doi: 10.1111/j.1399-5610.2010.00790.x
9. Accare. Formularium Psychofarmaca Accare; Monitoring op metabole en endocriene bijwerkingen van antipsychotica [Protocol: Monitoring for metabolic and endocrine adverse effects of antipsychotics]. (2014) Available online at: https://www.kenniscentrum-kjp.nl/app/webroot/files/tmpwebsite/Downloadable_PDFs_tabellen_en_overige/monitoring_bij_antipsychotica._2014.pdf (accessed April 2020).
10. National Institute for Health and Clinical Excellence (NICE). Psychosis and schizophrenia in children and young people: recognition and management; NICE Clinical Guideline 155. (2013) Available online at: http://www.nice.org.uk/guidance/gc155 (accessed August 2019).
11. Pringsheim T, Panagiotopoulos C, Davisson J, Ho J. The Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in Children (CAMESA) Guideline. Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth. J Can Acad Child Adolesc Psychiatry. (2011) 20:218–33.
12. Nederlof M, Stoker IJ, Egberts TCG, Heerdink ER. Instructions for clinical and biomarker monitoring in the Summary of product characteristics (SmPC) for psychotropic drugs: overview and applicability in clinical practice. J Psychopharmacol. (2015) 29:1248–54. doi: 10.1177/0269881115090936
13. Okumura Y, Usami M, Okada T, Saito T, Negoro H, Tsujii N, et al. Glucose and prolactin monitoring in children and adolescents initiating antipsychotic therapy. J Child Adolesc Psychopharmacol. (2018) 28:454–62. doi: 10.1089/cap.2018.0013
14. Minjon L, van den Ban E, de Jong E, Egberts TCG, Heerdink ER. Monitoring of metabolic, cardiac, and endocrine indicators in young treated with antipsychotics as reported by health care professionals. J Clin Psychopharmacol. (2018) 38:489–93. doi: 10.1097/JCP.0000000000000936
15. Delate T, Kauffman YS, Botts SR, Wong C, Gaughan KM. Metabolic monitoring in commercially insured pediatric patients newly initiated to take a second-generation antipsychotic. JAMA Pediatr. (2014) 168:679–81. doi: 10.1001/jamapediatrics.2014.224
16. Hayden JD, Horder L, Parsons T, Ruble M, Townsend S, Klein CC, et al. Metabolic monitoring rates of youth treated with second-generation antipsychotics in usual care: results of a large US national commercial health plan. J Child Adolesc Psychopharmacol. (2020) 30:119–22. doi: 10.1089/cap.2019.0087
17. van den Akker ELT, Vreugdenhil A, Hustinx SR, Verkaaij M, Houdijk M, van Mil E. Obesitas bij kinderen en adolescenten; leidraad voor kinderartsen [Obesity in children and adolescents; guidance for pediatricians]. (2018). Available online at: https://www.nvcl.nl/themas/kwaliteit/richtlijnen/richtlijn/componentid=7864323&ttag=Endocrinologie%2cMaag-Darm-Leverziekten%2bMDL%2cObesitas. (accessed February 2021).
18. Wakefield S, Aligeti M, Rachamallu V, Baronia R, Aynampudi R, Parmar A, Peterson P, Masodkar K. Metabolic monitoring of child and adolescent patients on atypical antipsychotics by psychiatrists and primary care providers. Am J Ther. (2020) 27:e425–430. doi: 10.1097/MJT.0000000000000853
19. Rodday AM, Parsons SK, Mankiw C, Correll CU, Robb AS, Zima BT, et al. Child and adolescent psychiatrists’ reported monitoring behaviors for second-generation antipsychotics. J Child Adolesc Psychopharmacol. (2015) 25:351–61. doi: 10.1089/cap.2014.0156
20. Raebel MA, Penfold R, McMahon AW, Reichman M, Shetterly S, Goodrich G, et al. Adherence to guidelines for glucose assessment in starting second-generation antipsychotics. Pediatrics. (2014) 134:e1308–14. doi: 10.1542/peds.2014-0828
21. Morrato EH, Nolan GE, Maahs D, Druss BG, Hartung DM, Valuck RJ, et al. Metabolic screening in children receiving antipsychotic drug treatment. Arch Pediatr Adolesc Med. (2010) 164:344–51. doi: 10.1001/archpediatrics.2010.48
22. McLenon J, Rogers MAM. The fear of needles: a systematic review and meta-analysis. J Adv Nurs. (2019) 75:30–42. doi: 10.1111/jan.13818
23. American Academy of Child and Adolescent Psychiatry (AACAP). Practice parameter for the use of atypical antipsychotic medications in children and adolescents. (2011) Available online at: https://www.aacap.org/App_Themes/AACAP/docs/practice_parameters/Atypical_Antipsychotic_Medications_Web.pdf (accessed January 2021).
24. Cotes RO, Fernandes NK, McLaren JL, McHugo GI, Bartels SJ, Brunette MF. Improving cardiometabolic monitoring of children on antipsychotics. J Child Adolesc Psychopharmacol. (2017) 27:916–9. doi: 10.1089/cap.2017.0034
25. Pereira L, Budovich A, Claudio-Saez M. Monitoring of metabolic adverse effects associated with atypical antipsychotics use in an outpatient psychiatric clinic. J Pharm Pract. (2019) 32:388–93. doi: 10.1177/0897190119775272
26. Nederlof M, Egberts TCG, van Londen L, de Rotte MCFJ, Souverein PC, Herings RMC, et al. Compliance with the guidelines for laboratory monitoring of patients treated with lithium: a retrospective follow-up study among ambulatory patients in the Netherlands. Bipolar Discord. (2019) 21:419–27. doi: 10.1111/bdi.12730
27. Lavon O, Goldman R. Adherence to monitoring guidelines of amiodarone adverse reactions. Heal Serv Res Manag Epidemiol. (2019) 6:1–4. doi: 10.21333/2019/044635
28. Schmidt M, Mansfield KE, Bhaskaran K, Nitsch D, Sorensen HT, Smeeth L, et al. Adherence to guidelines for creatinine and potassium monitoring and discontinuation following remin-angiotensin system blockade: a UK general practice-based cohort study. BMJ Open. (2017) 7:e012818. doi: 10.1136/bmjopen-2016-012818
29. Ronslø R, Raghuuram K, Davidson J, Panagiotopoulos C. Barriers and facilitators to implementation of a metabolic monitoring protocol in hospital and community settings for second-generation antipsychotic-treated youth. J Can Acad Child Adolesc Psychiatry. (2011) 20:134–41.
30. Parameswaran SG, Chang C, Swenson AK, Shumway M, Olifon M, Mangurian CV. Roles in and barriers to metabolic screening for people taking antipsychotic medications: a survey of psychiatrists. Schizophr Res. (2013) 143:395–6. doi: 10.1016/j.schres.2012.08.031
31. Mangurian C, Giwa F, Shumway M, Fuentes-Afflick E, Pérez-Stable EJ, Dilley JW, et al. Primary care providers’ views on metabolic monitoring of outpatients taking antipsychotic medication. Psychiatr Serv. (2013) 64:597–9. doi: 10.1176/appi.ps.002542012
32. Burke HB, Sessums LL, Hoang A, Becher DA, Fontelo P, Liu F, et al. Electronic health records improve clinical note quality. J Am Med Informatics Assoc. (2015) 22:199–205. doi: 10.1136/amiajnl-2014-002726
33. Soto CM, Kleinman KP, Simon SR. Quality and correlates of medical record documentation in the ambulatory care setting. BMC Health Serv Res. (2002) 2:22. doi: 10.1186/1472-6963-2-22
34. Rameraman L, Hoekstra PJ, de Kuiper G. Exploring barriers and facilitators in the implementation and use of guideline recommendations on antipsychotic drug prescriptions for people with intellectual disability. J Appl Res Intellectual Disabil. (2018) 31:1062–70. doi: 10.1111/jar.12461
35. McLaren JL, Brunette MF, McHugo GI, Drake RE, Daviss WB. Monitoring of patients on second-generation antipsychotics: a national survey of child psychiatrists. Psychiatr Serv. (2017) 68:958–61. doi: 10.1176/appi.ps.201500553
36. Nederlof M, Cath DC, Stoker IJ, Egberts TCG, Heerdink ER. Guidance by physicians and pharmacists during antidepressant therapy: patients’
needs and suggestions for improvement. *BMC Psychiatry.* (2017) 17:388. doi: 10.1186/s12888-017-1522-9

37. Galling B, Roldán A, Nielsen RE, Nielsen J, Gerhard T, Carbon M, et al. Type 2 diabetes mellitus in youth exposed to antipsychotics. A systematic review and meta-analysis. *JAMA Psychiatry.* (2016) 73:247–59. doi: 10.1001/jamapsychiatry.2015.52923

38. Roke Y, van Harten PN, Boot AM, Buitelaar JK. Antipsychotic medication in children and adolescents: a descriptive review of the effects on prolactin level and associated side effects. *J Child Adolesc Psychopharmacol.* (2009) 19:403–14. doi: 10.1089/cap.2008.0120

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Minjon, Brozina, Egberts, Heerdink and van den Ban. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.